000			02166cam a2200313 4500500
005			20250121162826.0
041			_afre
042			_adc
100	1	0	_aGuo, Hong-Li _eauthor
700	1	0	_a Dong, Na _eauthor
700	1	0	_a Chen, Feng _eauthor
700	1	0	_a Zeng, Yuan-Yuan _eauthor
700	1	0	_a Hu, Ya-Hui _eauthor
700	1	0	_a Xia, Ying _eauthor
700	1	0	_a Tian, Man _eauthor
700	1	0	_a Lu, Xiao-Peng _eauthor
700	1	0	_a Qiu, Jin-Chun _eauthor
245	0	0	_aEffect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis
260			_c2022.
500			_a3
520			_aObjective Despite the potential role of valproic acid (VPA) in weight gain, the effects of VPA therapy on lipid profiles remain unclear. This study aimed to review the influence of VPA therapy on serum lipid profiles in children with epilepsy. Methods This meta-analysis was conducted on data from PubMed, Web of Science, Cochrane Library, and Embase databases. Case-controlled studies, which assessed the effects of VPA therapy on lipid profiles, were included. All outcomes were recorded as continuous variables, and the effect size was measured. Results VPA therapy was associated with a significant reduction in total cholesterol (mean difference [MD]=-6.34, 95% confidence interval [CI]: -12.30, -0.37, p=0.04) and low-density lipoprotein cholesterol levels (MD = -7.75, 95% CI: -13.48, -2.0, p=0.008). No significant effects were observed regarding the levels of high-density lipoprotein cholesterol and triglycerides. Significance In conclusion, this meta-analysis indicates that VPA therapy causes a decrease in the levels of total cholesterol and low-density lipoprotein cholesterol.
690			_atotal cholesterol (TC)
690			_avalproic acid
690			_atriglycerides (TG)
690			_ahigh-density lipoprotein cholesterol (HDL-C)
690			_alow-density lipoprotein cholesterol (LDL-C)
786	0		_nEpileptic Disorders | Vol 24 | 5 | 2022-05-01 | p. 822-830 | 1294-9361
856	4	1	_uhttps://shs.cairn.info/revue-epileptic-disorders-2022-5-page-822?lang=en&redirect-ssocas=7080
999			_c612418 _d612418